SRRM4 and prostate adenocarcinoma: Further comparison of SRRM4 gene expression levels among NEPC, metastatic castration-resistant prostate cancer (CRPC), and primary prostate adenocarcinoma (PRAD) samples revealed that overexpression of SRRM4 is unique to NEPC (Fig. 3F), a finding that is consistent with a previous report (37).